Clinical data and observational studies from 2025 show measurable reductions in addiction behavior, anxiety symptoms, and depression markers among GLP-1 users — effects that were not the drugs' design target. The mechanism may be the most important finding in psychiatry in a generation.
For the first time, clinical interventions targeting biological aging have produced statistically significant human results — and the timeline for market availability has compressed in ways the longevity field has not yet fully communicated.
After a decade of overhyped promises, microbiome science is producing reproducible clinical results in specific conditions. The interventions that work, and why they work, reveal a biology far stranger and more consequential than the popular science version.
A new generation of neuroscientists believes it can selectively erase traumatic memories. They may be right. The harder question is whether they should.
GLP-1 drugs are the most significant advance in obesity medicine in decades. They are also revealing how little we understood about obesity — and how much we still don't.
We have known for decades that Americans are not sleeping enough and that this is making us sicker, dumber, and more dangerous. We have done almost nothing about it.
Private equity has acquired thousands of medical practices, hospitals, and care facilities. The returns have been good. The patient outcomes are a different story.
Billions are flowing into research that promises to add decades to the human lifespan. The science is more serious than the hype — and more uncertain than the investors admit.
Metabolic disease — obesity, type 2 diabetes, cardiovascular disease, fatty liver — now accounts for the majority of US healthcare spending. The dietary signals that predicted this have been visible for decades.